Transition from intramuscular ziprasidone to oral formulation in agitated inpatients with acute exacerbation of schizophrenia: A 7+N days, open-labeled, single-arm, multicenter and prospective study

Trial Profile

Transition from intramuscular ziprasidone to oral formulation in agitated inpatients with acute exacerbation of schizophrenia: A 7+N days, open-labeled, single-arm, multicenter and prospective study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Ziprasidone (Primary) ; Ziprasidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top